Paradoxic effects of metformin on endothelial cells and angiogenesis
Katiuscia Dallaglio, Antonino Bruno, Anna R Cantelmo, Alessia I Esposito, Luca Ruggiero, Stefania Orecchioni, Angelica Calleri, Francesco Bertolini, Ulrich Pfeffer, Douglas M Noonan, Adriana Albini, Katiuscia Dallaglio, Antonino Bruno, Anna R Cantelmo, Alessia I Esposito, Luca Ruggiero, Stefania Orecchioni, Angelica Calleri, Francesco Bertolini, Ulrich Pfeffer, Douglas M Noonan, Adriana Albini
Abstract
The biguanide metformin is used in type 2 diabetes management and has gained significant attention as a potential cancer preventive agent. Angioprevention represents a mechanism of chemoprevention, yet conflicting data concerning the antiangiogenic action of metformin have emerged. Here, we clarify some of the contradictory effects of metformin on endothelial cells and angiogenesis, using in vitro and in vivo assays combined with transcriptomic and protein array approaches. Metformin inhibits formation of capillary-like networks by endothelial cells; this effect is partially dependent on the energy sensor adenosine-monophosphate-activated protein kinase (AMPK) as shown by small interfering RNA knockdown. Gene expression profiling of human umbilical vein endothelial cells revealed a paradoxical modulation of several angiogenesis-associated genes and proteins by metformin, with short-term induction of vascular endothelial growth factor (VEGF), cyclooxygenase 2 and CXC chemokine receptor 4 at the messenger RNA level and downregulation of ADAMTS1. Antibody array analysis shows an essentially opposite regulation of numerous angiogenesis-associated proteins in endothelial and breast cancer cells including interleukin-8, angiogenin and TIMP-1, as well as selective regulation of angiopioetin-1, -2, endoglin and others. Endothelial cell production of the cytochrome P450 member CYP1B1 is upregulated by tumor cell supernatants in an AMPK-dependent manner, metformin blocks this effect. Metformin inhibits VEGF-dependent activation of extracellular signal-regulated kinase 1/2, and the inhibition of AMPK activity abrogates this event. Metformin hinders angiogenesis in matrigel pellets in vivo, prevents the microvessel density increase observed in obese mice on a high-fat diet, downregulating the number of white adipose tissue endothelial precursor cells. Our data show that metformin has an antiangiogenic activity in vitro and in vivo associated with a contradictory short-term enhancement of pro-angiogenic mediators, as well as with a differential regulation in endothelial and breast cancer cells.
Figures
References
- Evans J.M., et al. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304–1305
- Zhang P., et al. (2013). Association of metformin use with cancer incidence and mortality:a meta-analysis. Cancer Epidemiol., 37, 207–218
- Ben Sahra I., et al. (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576–3586
- Phoenix K.N., et al. (2009). Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat., 113, 101–111
- Akinyeke T., et al. (2013) Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis, 34, 2823–2832
- Eid A.A., et al. (2010) AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J. Biol. Chem., 285, 37503–37512
- Tan B.K., et al. (2009). Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc. Res., 83, 566–574
- Xavier D.O., et al. (2010). Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed. Pharmacother., 64, 220–225
- Esfahanian N., et al. (2012). Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells. Mol. Med. Rep., 5, 1068–1074
- Albini A., et al. (2012). Cancer prevention by targeting angiogenesis. Nat. Rev. Clin. Oncol., 9, 498–509
- Chung A.S., et al. (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer, 10, 505–514
- Mann J.R., et al. (2005). Mechanisms of disease:inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol., 2, 202–210
- Albini A., et al. (2007). The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer, 7, 139–147
- Ersoy C., et al. (2008). The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res. Clin. Pract., 81, 56–60
- Lund S.S., et al. (2008). Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur. J. Endocrinol., 158, 631–641
- Hirsch H.A., et al. (2013). Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl Acad. Sci. USA, 110, 972–977
- Caballero A.E., et al. (2004). The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab., 89, 3943–3948
- Abbasi F., et al. (2004). Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism., 53, 159–164
- Cacicedo J.M., et al. (2004). AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun., 324, 1204–1209
- De Jager J., et al. (2005). Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med., 257, 100–109
- Hadad S.M., et al. (2009). Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat., 114, 391.
- Martin M.J., et al. (2012). Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov., 2, 344–355
- Cittadini A., et al. (2012). Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes, 61, 944–953
- Sena C.M., et al. (2011). Metformin restores endothelial function in aorta of diabetic rats. Br. J. Pharmacol., 163, 424–437
- Ziche M., et al. (2009). Molecular regulation of tumour angiogenesis by nitric oxide. Eur. Cytokine Netw., 20, 164–170
- Carpentier G. (2012). Contribution:angiogenesis analyzer. ImageJ News, 5 October 2012. (21 October 2013, date last accessed).
- Passaniti A., et al. (1992). A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest., 67, 519–528
- Balwierz A., et al. (2009). Angiogenesis in the New Zealand obese mouse model fed with high fat diet. Lipids Health Dis., 8, 13.
- Martin-Padura I., et al. (2012). The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression. Cancer Res., 72, 325–334
- Mancuso P., et al. (2011). Circulating perivascular progenitors: a target of PDGFR inhibition. Int. J. Cancer, 129, 1344–1350
- Dagher Z., et al. (1999). The effect of AMP-activated protein kinase and its activator AICAR on the metabolism of human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun., 265, 112–115
- Ido Y., et al. (2002). Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes, 51, 159–167
- Nagata D., et al. (2003) AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J. Biol. Chem., 278, 31000–31006
- Ouchi N., et al. (2004) Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem., 279, 1304–1309
- Shibata R., et al. (2004) Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J. Biol. Chem., 279, 28670–28674
- Hattori Y., et al. (2006). Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension, 47, 1183–1188
- Baud V., et al. (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov., 8, 33–40
- Jalving M., et al. (2010). Metformin: taking away the candy for cancer? Eur. J. Cancer, 46, 2369–2380
- Wong C., et al. (2005) Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor. J. Biol. Chem., 280, 33262–33269
- To K.K., et al. (2006). The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J., 25, 4784–4794
- Teicher B.A., et al. (2010). CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res., 16, 2927–2931
- Tang Y., et al. (2010). CYP1B1 and endothelial nitric oxide synthase combine to sustain proangiogenic functions of endothelial cells under hyperoxic stress. Am. J. Physiol. Cell Physiol., 298, C665–C678
- Tang Y., et al. (2009). CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression. Blood, 113, 744–754
- Palomba S., et al. (2013). Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG, 120, 267–276
- Rattan R., et al. (2011). Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo . Neoplasia, 13, 483–491
- Liao H., et al. (2012). Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol. Rep., 27, 1873–1878
- Obika M., et al. (2012). Tumor growth inhibitory effect of ADAMTS1 is accompanied by the inhibition of tumor angiogenesis. Cancer Sci., 103, 1889–1897
- Ware W.R. (2009). Nutrition and the prevention and treatment of cancer: association of cytochrome P450 CYP1B1 with the role of fruit and fruit extracts. Integr. Cancer Ther., 8, 22–28
- Luby T.M. (2008). Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine. Expert Rev. Vaccines, 7, 995–1003
- Conway D.E., et al. (2009). Expression of CYP1A1 and CYP1B1 in human endothelial cells: regulation by fluid shear stress. Cardiovasc. Res., 81, 669–677
- Weis S.M., et al. (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 17, 1359–1370
- Mikstacka R., et al. (2007). Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. Mol. Nutr. Food Res., 51, 517–524
- Guedez L., et al. (2001). Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt’s lymphoma via divergent effects on tumor growth and angiogenesis. Am. J. Pathol., 158, 1207–1215
- Gou S., et al. (2013). Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action. PLoS One, 8, e63969.
- Ye J., et al. (2013). Inflammation during obesity is not all bad: evidence from animal and human studies. Am. J. Physiol. Endocrinol. Metab., 304, E466–E477
Source: PubMed